{"groups":[{"description":"Subjects will receive carfilzomib 20 mg/m2 intravenously on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles","id":"FG000","title":"Carfilzomib (A0)"},{"description":"In Cycle 1, subjects will receive carfilzomib 20 mg/m2 intravenously on Days 1, 2, 8, 9, 15, and 16. If all doses are administered and well-tolerated over the 28-day cycle, beginning with Cycle 2 the dose will escalate to 27 mg/m2 intravenously on Days 1, 2, 8, 9, 15, and 16 for all subsequent cycles.","id":"FG001","title":"Carfilzomib (A1)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"33"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"22"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"23"},{"groupId":"FG001","numSubjects":"157"}],"type":"Progressive Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"14"}],"type":"various reasons"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"46"},{"groupId":"FG001","numSubjects":"266"}],"type":"STARTED"},{"achievements":[{"comment":"Number of patients who completed 12 cycles of treatment","groupId":"FG000","numSubjects":"4"},{"comment":"Number of patients who completed 12 cycles of treatment","groupId":"FG001","numSubjects":"40"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"42"},{"groupId":"FG001","numSubjects":"226"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Results of this study are reported in 2 parts, depending on whether a patient was enrolled and treated under the original protocol (referred to as 'A0') or under Amendment 1 and subsequent amendments (referred to as 'A1')."}